| Bioactivity | Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile[1]. |
| Target | estrogen |
| Invitro | Arzoxifene reduces estrogen receptor expression in endometrial cancer cell lines (ECC-1)[1]. |
| In Vivo | Arzoxifene inhibits MCF-7 breast cancer xenograft growth in oophorectomized athymic mice. Arzoxifene is reported to prevent body weight increase in oophorectomized rats[1]. |
| Name | Arzoxifene |
| CAS | 182133-25-1 |
| Formula | C28H29NO4S |
| Molar Mass | 475.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jackson LR, et al. Arzoxifene: the evidence for its development in the management of breast cancer. Core Evid. 2008;2(4):251-258. |
Arzoxifene
CAS: 182133-25-1 F: C28H29NO4S W: 475.60
Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to r
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.